Experimental Drug Combination 'Encouraging' in Relapsed Multiple Myeloma
Monday, December 12, 2011 - 20:30
in Health & Medicine
Dana-Farber Cancer Institute researchers say when the targeted drug bortezomib stops working in patients with advanced multiple myeloma, the patients survive only an average of five months longer. But a phase 2 clinical trial has shown that pairing bortezomib with an experimental drug, panobinostat, may be a promising new treatment for such patients.